← Back to Search

F-18 Fluorodopa PET Scan for Brain Tumor

Q: Is there any availability for participants in this trial?

<p>Unfortunately, clinicaltrials.gov reports that this medical trial is not presently enrolling patients; however, it was originally posted on July 26th 2010 and last updated April 8th 2022. Fortunately, there are currently 740 other studies searching for participants.</p>

Phase < 1

Waitlist Available

Research Sponsored by Mayo Clinic

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Planned craniotomy and resection or biopsy

MRI findings compatible with newly diagnosed high- or low-grade malignant glioma

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 2 years

Awards & highlights

Study Summary

This trial will study how well fluorine F 18 fluorodopa-labeled PET scan works in planning surgery and radiation therapy in treating patients with newly diagnosed high- or low-grade malignant glioma.

Who is the study for?

This trial is for adults over 18 with a new diagnosis of high or low-grade malignant glioma, who are planning to have brain surgery (craniotomy and resection or biopsy). Participants must be able to provide medical records and consent. Women capable of becoming pregnant must test negative for pregnancy within 48 hours before receiving the study drug.Check my eligibility

What is being tested?

The trial studies how well a special PET scan using fluorine F 18 fluorodopa works in planning surgical and radiation treatments for brain tumors. It aims to improve treatment by providing better imaging techniques to guide doctors during these procedures.See study design

What are the potential side effects?

While not directly related to side effects from medications, this trial involves exposure to radiation through PET scans and potential risks associated with magnetic resonance imaging (MRI), surgery, and radiation therapy which can include discomfort, bleeding, infection, or allergic reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am scheduled for brain surgery to remove or sample a tumor.

Select...

My MRI shows I might have a serious brain tumor.

Select...

I am 18 years old or older.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

18F- FDOPA-PET metabolic imaging information

18F-FDOPA PET activity, MRI contrast enhancement, and high- or low-grade glioma biopsies

Secondary outcome measures

18F-FDOPA PET activity, 11C-choline PET activity, MRI contrast enhancement, pMRI, and DTI, with high- or low-grade glioma biopsies

Concordance of 18F-FDOPA PET and 11C-choline activity, MRI contrast enhancement, and high- or low-grade glioma biopsies

With and without 18F- FDOPA PET, 11C-choline PET metabolic imaging information

Trial Design

1Treatment groups

Experimental Treatment

Group I: Arm IExperimental Treatment8 Interventions

Beginning at no more than 1 week before biopsy or resection, patients undergo fluorine F 18 fluorodopa-labeled PET/CT scan and pre-operative MRI. Patients then undergo stereotactic craniotomy. Some patients may also undergo radiation therapy.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

therapeutic conventional surgery

2003

Completed Phase 3

~12270

magnetic resonance imaging

2002

Completed Phase 2

~1820

positron emission tomography

2010

Completed Phase 2

~1370

radiation therapy

1994

Completed Phase 3

~13390

biopsy

2002

Completed Phase 4

~8270

computed tomography

2010

Completed Phase 2

~1200

radiation therapy treatment planning/simulation

2009

Completed Phase 1

~50

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH

13,654 Previous Clinical Trials

40,933,129 Total Patients Enrolled

Mayo ClinicLead Sponsor

3,205 Previous Clinical Trials

3,766,760 Total Patients Enrolled

Nadia N. Laack, M.D.Study ChairMayo Clinic

2 Previous Clinical Trials

19 Total Patients Enrolled

Media Library

Radiation Therapy Clinical Trial Eligibility Overview. Trial Name: NCT01165632 — Phase < 1

Anaplastic Ependymoma Research Study Groups: Arm I

Anaplastic Ependymoma Clinical Trial 2023: Radiation Therapy Highlights & Side Effects. Trial Name: NCT01165632 — Phase < 1

Radiation Therapy 2023 Treatment Timeline for Medical Study. Trial Name: NCT01165632 — Phase < 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is there any availability for participants in this trial?

"Unfortunately, clinicaltrials.gov reports that this medical trial is not presently enrolling patients; however, it was originally posted on July 26th 2010 and last updated April 8th 2022. Fortunately, there are currently 740 other studies searching for participants."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant Glioma

2010. "Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant Glioma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01165632.

All > Ependymoma > Oligodendroglioma